Humana Inc. $HUM Shares Sold by Newport Trust Company LLC

Newport Trust Company LLC trimmed its position in shares of Humana Inc. (NYSE:HUM) by 7.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 985,738 shares of the insurance provider’s stock after selling 80,796 shares during the quarter. Humana accounts for approximately 0.6% of Newport Trust Company LLC’s portfolio, making the stock its 26th largest holding. Newport Trust Company LLC’s holdings in Humana were worth $252,477,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Montag A & Associates Inc. boosted its holdings in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after buying an additional 94 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Rosenberg Matthew Hamilton boosted its holdings in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after buying an additional 81 shares in the last quarter. Finally, Fulcrum Asset Management LLP purchased a new stake in Humana during the third quarter worth about $42,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 0.3%

Shares of NYSE HUM opened at $303.13 on Friday. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $315.66. The company has a market capitalization of $36.39 billion, a PE ratio of 32.42, a price-to-earnings-growth ratio of 2.83 and a beta of 0.68. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The firm’s 50-day moving average is $215.40 and its two-hundred day moving average is $227.07.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter in the prior year, the firm earned $11.58 earnings per share. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. Equities analysts anticipate that Humana Inc. will post 9 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio is 37.86%.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of research analyst reports. Morgan Stanley boosted their price objective on shares of Humana from $146.00 to $217.00 and gave the stock an “underweight” rating in a report on Friday, May 15th. JPMorgan Chase & Co. boosted their price objective on shares of Humana from $180.00 to $214.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Oppenheimer raised shares of Humana from an “outperform” rating to an “outperform” rating in a report on Wednesday. Guggenheim boosted their price objective on shares of Humana from $252.00 to $269.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Evercore boosted their price objective on shares of Humana from $195.00 to $250.00 in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $260.83.

Insider Activity

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction on Monday, February 23rd. The shares were bought at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the acquisition, the insider directly owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.